|
|
 |
|
 |
Mike Hurst, RPh , MBA Expert resource in hospital pharmacy safety, including issues relating to USP 797, pharmaceutical compounding, sterile preparations, oral medication dispensers, enteral feeding misconnections, isolators, syringe batch processing, risk assessment of compounded sterile preparations, and safe handling of hazardous drugs. |
||||||
|
Michael Hurst RPh, MBA worked for 18 years at Swedish Medical Center in Seattle, Washington in operational management, including positions as IV Supervisor and Assistant Director of Pharmacy. His implementation of a syringe infusion system in 1984 had national implications. For the next 9 years Mike wrote, spoke, consulted and acted as a reference site for syringe infusion installations across the country. |
||||||
"How To Prevent Infection From IV Therapy Complications" A Baxa Corporation Bylined Article by Mike Hurst, RPh , MBA Healthcare-associated infections are a staggering cause of increased provider costs and morbidity in the United States; and intravenous therapy complications are a major contributor to bloodstream infections. A new Mike Hurst-bylined article is now posted at the “Expert Information for Journalists” site about this topic. Hurst reviews the problem and gives perspective to what nurses surveyed know and believe about IV therapy complications. "USP Chapter <797>: Understanding the Revisions" A Baxa Corporation Technical Paper by Mike Hurst, RPh , MBA USP Chapter <797> became official on January 1, 2004. The first major revision was released on December 3, 2007, following years of soliciting feedback and the review of hundreds of responses by the USP Sterile Compounding Committee. June 1, 2008, is the effective date for the new standards. This paper summarizes the most important changes to USP <797>. If you would like to submit a question by e-mail, click here. In addition, links follow to additional Baxa Corporation technical papers authored by Mike Hurst: |
||||||
|
|
||||||
|
 |